Merk, Daniel J. http://orcid.org/0000-0003-2935-6919
Paul, Linda http://orcid.org/0009-0005-7830-2775
Tsiami, Foteini http://orcid.org/0009-0001-6070-0434
Hohenthanner, Helen http://orcid.org/0009-0000-3761-4776
Kouchesfahani, Ghazal Mohseni http://orcid.org/0009-0001-3156-7929
Haeusser, Lara A. http://orcid.org/0000-0002-3288-4280
Walter, Bianca http://orcid.org/0000-0001-9734-4843
Brown, Adam
Persky, Nicole S. http://orcid.org/0000-0002-9948-2761
Root, David E. http://orcid.org/0000-0001-5122-861X
Tabatabai, Ghazaleh http://orcid.org/0000-0002-3542-8782
Funding for this research was provided by:
Medizinischen Fakultät, Eberhard Karls Universität Tübingen (2626-0-1)
Deutsche Forschungsgemeinschaft (Cluster of Excellence-EXC 2180-390900677)
Adolf Leuze Stiftung
Medical Faculty of the University of Tübingen (Demonstratorprojekt Personalized Medicine)
Article History
Received: 9 November 2023
Accepted: 30 April 2024
First Online: 17 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: GT has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as steering committee member in non-interventional trials (Bayer, Novocure), and as a speaker (Novocure, Servier), and financial compensation for all these activities was provided as institutional funding to the University Hospital Tübingen. DER receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir) and is a director of Addgene, Inc. The remaining authors declare that they do not have any competing interests.